皮下注射胸腺五肽治疗伴有持续性全身淋巴结肿大的吸毒者的疗效
Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy.
作者信息
Barcellini W, Meroni P L, Frasca D, Sguotti C, Borghi M O, Uberti-Foppa C, Buzzetti P, Lazzarin A, Doria G, Moroni M
出版信息
Clin Exp Immunol. 1987 Mar;67(3):537-43.
The effect of thymopentin treatment on the immune defects in drug addicts with persistent generalized lymphadenopathy and HTLV-III infection was investigated. Thymopentin was administered subcutaneously at two different dose schedules: 50 mg three times a week for 3 weeks (first cycle) and 50 mg/week for 3 months (second cycle). After the first cycle an increased number of OKT4+ lymphocytes and an improvement of PWM-induced blastogenesis and IgG synthesis in vitro was observed. The second cycle was unable to modify the same immune parameters in vitro. The treatment had no effect on the PHA responsiveness and on PHA-induced interleukin 2 production. The significance and the prognostic value of these findings are discussed in terms of the clinical evolution of the syndrome.
研究了胸腺五肽治疗对患有持续性全身性淋巴结病和HTLV-III感染的吸毒者免疫缺陷的影响。胸腺五肽按两种不同的给药方案皮下注射：每周三次，每次50mg，共3周（第一周期）；每周50mg，共3个月（第二周期）。第一周期后，观察到OKT4 +淋巴细胞数量增加，体外PWM诱导的淋巴细胞增殖和IgG合成得到改善。第二周期未能在体外改变相同的免疫参数。该治疗对PHA反应性和PHA诱导的白细胞介素2产生没有影响。根据该综合征的临床演变讨论了这些发现的意义和预后价值。
Zotero 插件